EASI Score: 5-Step Guide To Accurate Atopic Eczema Assessment

What is an

EASI score

?
An

EASI score

is a tool used to measure the extent (area) and severity of

atopic eczema

(*Eczema Area and Severity Index*).
It takes a few minutes and experience to calculate it accurately. Then it’s easy!

What is the EASI score used for?

The

Eczema Area and Severity Index (EASI)

is a validated tool recommended by the Harmonising Outcome Measures for Eczema (HOME) initiative as the core instrument for assessing clinical signs of atopic dermatitis (AD) in clinical trials. It provides a composite score ranging from 0 (clear skin) to 72 (most severe disease), combining percent body surface area (BSA) affected and intensity of lesions across four body regions: head and neck, upper limbs, trunk, and lower limbs.

Developed by modifying the Psoriasis Area and Severity Index (PASI), the EASI demonstrates high reliability, validity, and sensitivity to change. Studies involving thousands of participants confirm good intra- and inter-evaluator reliability.

In practice, EASI tracks treatment response through endpoints like EASI-75 (≥75% improvement), EASI-90, or EASI-100, facilitating objective comparisons in research and routine care.

Who does the EASI score?

The EASI must be performed by trained investigators or clinicians experienced in dermatological assessments. It requires approximately 6 minutes per evaluation once proficient.

Patient self-assessment versions exist but lack the validation of clinician-rated EASI. Consistent training ensures reproducibility across evaluators.

How is the EASI score calculated?

The EASI calculation follows a standardized, stepwise process assessing four body regions separately, then combining scores with region-specific multipliers reflecting BSA proportions in adults.

Step 1: Select the body regions

Divide the body into four regions:

• Head and neck (includes entire scalp, face, ears, neck)
• Upper extremities (arms, hands; each arm scored separately then averaged)
• Trunk (chest, abdomen, back, buttocks, groin)
• Lower extremities (legs, feet; each leg scored separately then averaged)

*Author’s note: Hands and feet follow extremity scoring despite palms/soles thickness.*

Step 2: Score the area of involvement in each region (A)

Estimate the percentage of BSA affected by active eczema in each region using this 7-point scale (half points allowed between 1-3):

Score	BSA Affected
0	0%
1	1-9%
2	10-29%
3	30-49%
4	50-69%
5	70-89%
6	90-100%: entire region affected

Key rules: Score only inflamed eczematous areas (red, infiltrated). Exclude post-inflammatory pigment changes, resolved areas, or dryness/scaling without inflammation. Use palpable landmarks (joints) for boundaries.

Step 3: Score severity of signs in each region

Assess average intensity across the region for four signs on 0-3 scale (0=none, 1=mild, 2=moderate, 3=severe):

• Erythema (redness)
• Infiltration/Papulation/Edema (thickness/swelling/papules)
• Excoriation (scratch marks)
• Lichenification (skin thickening)

Severity score = sum of four sign scores (0-12 per region).

Step 4: Calculate regional scores

Regional score = Severity score (0-12) × Area score (0-6) × Region multiplier:

Region	Multiplier	% BSA (Adults)
Head/Neck	0.1	10%
Upper Limbs	0.2	20%
Trunk	0.3	30%
Lower Limbs	0.4	40%

Total EASI = Sum of 4 regional scores (range 0-72).

Formula:
EASI = 0.1(E_h + I_h + Ex_h + L_h)A_h + 0.2(E_u + I_u + Ex_u + L_u)A_u + 0.3(E_t + I_t + Ex_t + L_t)A_t + 0.4(E_l + I_l + Ex_l + L_l)A_l

Step 5: Paediatric adjustment (age ≤7 years)

For children ≤7 years, use adjusted multipliers: Head=0.2, Lower limbs=0.3 (trunk/upper limbs unchanged).

Example calculation

Patient example: Adult male with head (area=2, signs=1+1+0+1=3), upper limbs (area=3, signs=2+2+1+1=6), trunk (area=1, signs=1+1+1+0=3), lower limbs (area=4, signs=2+2+2+2=8).

• Head: 3×2×0.1 = 0.6
• Upper: 6×3×0.2 = 3.6
• Trunk: 3×1×0.3 = 0.9
• Lower: 8×4×0.4 = 12.8
• Total EASI = 18.0 (moderate)

EASI score interpretation

Standard severity strata validated across studies:

EASI Score	Severity
0	Clear
0.1–1.0	Almost clear
1.1–7.0	Mild
7.1–21.0	Moderate
21.1–50.0	Severe
50.1–72.0	Very severe

These cutoffs show substantial agreement with investigator global assessment (κ=0.75).

Advantages and limitations of EASI

Advantages

• Validated: Excellent reliability, validity, responsiveness per HOME initiative
• Comprehensive: Integrates area + intensity
• Quick: ~6 minutes by trained users
• Standardised: Enables trial comparisons, EASI-75 endpoint

Limitations

• Subjective elements in area/intensity estimation
• Excludes dryness/scaling (common in eczema)
• Ceiling effect: max 72 underestimates extreme cases
• Requires training for consistency
• Less sensitive for mild disease or small changes

Clinical use and trial endpoints

EASI guides treatment escalation: mild (topicals), moderate-severe (systemics/biologics). In trials, ≥75% improvement (EASI-75) indicates excellent response.

Performed at baseline and follow-up visits as static measure of current severity.

EASI training resources

• HOME EASI User Guide (pdf)
• Standardized training modules improve inter-rater reliability
• Practice on diverse eczema presentations

Frequently asked questions

What does EASI stand for?

**Eczema Area and Severity Index** — composite score (0-72) measuring atopic eczema extent and clinical sign intensity across body regions.

How long does EASI take?

Approximately

6 minutes

by trained investigators.

Does EASI include dryness?

No. EASI scores only

four inflammatory signs

(erythema, edema/papulation, excoriation, lichenification). Dryness/scaling excluded.

What if eczema affects palms/soles?

Score as part of

extremities

. Palms/soles thickness doesn’t change regional assignment.

Can patients self-score EASI?

Not recommended.

Clinician-assessed

EASI is validated. Patient versions under development lack full validation.

Paediatric EASI multipliers?

≤7 years:

Head=0.2

,

Lower limbs=0.3

(reflects infant proportions).

EASI-75 means what?

≥**75% reduction** from baseline EASI. Common trial success criterion.